MiNK Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 19.14K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 4.17K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 84.46K shares, a 180.53% increase year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 96.89K shares, a 1205.20% increase from fiscal 2024.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 7.42K shares, a 29.43% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 10.52K shares, a 95.93% decline from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 258.65K shares, a 519.58% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 107.77K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 19.14K shares 10-Q · filed 2026-05-15 | |
| 2025-12-31 | 4.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 96.89K shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 84.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | |
| 2024-12-31 | -66.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 7.42K shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 30.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -20.44K shares derived: sum of 4 quarters · filed 2025-03-18 |
| 2024-06-30 | 28.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -39.41K shares derived: sum of 4 quarters · filed 2025-03-18 |
| 2024-03-31 | 15.47K shares 10-Q · filed 2024-05-14 | -35.86K shares derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-12-31 | -94.67K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 10.52K shares 10-K · filed 2025-03-18 |
| 2023-09-30 | 11.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 115.09K shares derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-06-30 | 32.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 220.19K shares derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-03-31 | 61.84K shares 10-Q · filed 2023-05-11 | 236.10K shares derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-12-31 | 9.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 258.65K shares 10-K · filed 2024-03-21 |
| 2022-09-30 | 116.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 248.75K shares derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-06-30 | 48.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | |
| 2022-03-31 | 84.39K shares 10-Q · filed 2022-05-13 | |
| 2021-12-31 | 1.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 41.75K shares 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |